BioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech SE (Nasdaq: BNTX, "BioNTech") and Biotheus ("Biotheus") today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.
In a report released today, Jorge Kuri from Morgan Stanley reiterated a Buy rating on Nu Holdings (NU – Research Report), with a price target of $18.00. Jorge Kuri’s rating is based on Nu ...
Barchart on MSN1h
2 Energy Dividend Stocks to Buy This November for Growth and IncomeAs oil prices remain volatile around thelatest OPEC+ moves and ongoing demand concerns, all eyes are on the energy sector, ...
Hosted on MSN1d
5 Semiconductor Stocks to Buy Now for More Upside in 2025The artificial intelligence (AI) megatrend has surged across markets over the last two years, generating substantial wealth ...
Nvidia stock has been the poster child for artificial intelligence and continues to defy the odds. But is the stock still a ...
BP p.l.c.'s recent management changes and strategic moves, including the Travel Centers of America acquisition, signal a ...
CDNS stock currently trades at around $234 and analysts hold a consensus price target of $253.34 for the stock with a Buy rating. Its software niche and innovation have helped Cadence maintain its ...
Bank of America has a "buy" rating and $240 price target for JPM stock, which closed at $236.98 on Nov. 8. Home Depot is one of the largest North American home improvement retailers. Analyst ...
MicroStrategy's market cap is significantly overvalued compared to its bitcoin holdings, with a premium near 3x. Learn more ...
Shares of Reddit Inc. were up 2.6% Wednesday after Jefferies initiated coverage of the social-media platform with a buy rating. Jefferies estimated that Reddit’s RDDT Ebitda will more than ...
Zino says new product launches at higher price points will also boost margins. CFRA has a "buy" rating and $139 price target for NVDA stock, which closed at $138 on Oct. 18. Low commission rates ...
Take a look at some of Benzinga’s favorites. You have found stocks to buy now cheap, but you need a partner that makes the process simple. When you choose the best broker for your situation ...
We recently compiled a list of the 15 AI News That Should Not Be Ignored. In this article, we are going to take a look at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback